D.E. Shaw & Co
NGNE icon

D.E. Shaw & Co’s Neurogene NGNE Stock Holding History

D.E. Shaw & Co’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
+9,781
New +$269K ﹤0.01% 4398
2026
Q1 		– Sell
-40,347
Closed -$831K – 4876
2025
Q4 		$831K Buy
+40,347
New +$1M ﹤0.01% 3650
2022
Q3 		– Sell
-9,821
Closed -$202K – 5410
2022
Q2 		$202K Buy
9,821
+1,215
+14% +$29.6K ﹤0.01% 4552
2022
Q1 		$324K Buy
8,606
+5,440
+172% +$317K ﹤0.01% 4612
2021
Q4 		$305K Buy
3,166
+1,858
+142% +$226K ﹤0.01% 4670
2021
Q3 		$189K Buy
+1,308
New +$200K ﹤0.01% 4583
2021
Q1 		– Sell
-857
Closed -$242K – 4337
2020
Q4 		$242K Buy
+857
New +$209K ﹤0.01% 3669
2020
Q3 		– Sell
-1,650
Closed -$548K – 4041
2020
Q2 		$548K Buy
1,650
+17
+1% +$4.43K ﹤0.01% 3304
2020
Q1 		$372K Sell
1,633
-2,943
-64% -$606K ﹤0.01% 3360
2019
Q4 		$1.13M Sell
4,576
-1,282
-22% -$128K ﹤0.01% 2897
2019
Q3 		$334K Sell
5,858
-460
-7% -$28.1K ﹤0.01% 3405
2019
Q2 		$298K Hold
6,318
– – ﹤0.01% 3316
2019
Q1 		$341K Sell
6,318
-8,914
-59% -$450K ﹤0.01% 3169
2018
Q4 		$658K Sell
15,232
-131
-0.9% -$6.38K ﹤0.01% 2932
2018
Q3 		$900K Buy
15,363
+13,936
+977% +$822K ﹤0.01% 2757
2018
Q2 		$76K Buy
1,427
+394
+38% +$103K ﹤0.01% 3632
2018
Q1 		$291K Buy
1,033
+104
+11% +$28.7K ﹤0.01% 3163
2017
Q4 		$218K Buy
929
+375
+68% +$87.9K ﹤0.01% 3399
2017
Q3 		$157K Buy
+554
New +$159K ﹤0.01% 3335

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

D.E. Shaw & Co's NGNE Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Neurogene (NGNE) in Q2 2026: 9,781 shares worth $308K. The stake represents ﹤0.01% of the portfolio and ranks #4398 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in NGNE as recently as Q4 2025.

D.E. Shaw & Co first reported a position in NGNE in Q3 2017 and has held it in 19 quarters since. The position peaked at $1.13M in Q4 2019. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • D.E. Shaw & Co held 9,781 shares of Neurogene worth $308K as of Q2 2026.
  • Neurogene was a new D.E. Shaw & Co position in Q2 2026.
  • Neurogene made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4398 holding.
  • D.E. Shaw & Co first reported a position in Neurogene in Q3 2017 and has held it in 19 quarters since.
  • D.E. Shaw & Co's Neurogene position peaked at $1.13M in Q4 2019.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.